Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
MonarchBio
AddedFeb 16, 2024
UpdatedJun 18, 2026
MonarchBio

MonarchBio

Seed

LA-based MonarchBio innovates in biotech, specializing in local delivery cell therapies for solid tumors.

HQ
Los Angeles, CA, US
Founded
2011
Overview
Compare
Fundraising
Employees
Website

MonarchBio, founded in Los Angeles, is a biotechnology company dedicated to revolutionizing cancer treatment through the local delivery of cell therapies specifically targeting solid tumors. The company leverages Thin Film Nitinol technology to develop next-generation medical devices and biotech products. MonarchBio's mission is to enhance the efficacy and precision of cancer treatments, aiming to improve patient outcomes and quality of life.

Notable figures affiliated with MonarchBio include leading experts in oncology and biotechnology. The company has attracted significant interest from investors focused on innovative cancer therapies. Key achievements include the successful development and commercialization of their proprietary Thin Film Nitinol-based products. MonarchBio's impact is marked by its potential to transform cancer treatment protocols, offering more targeted and effective therapeutic options for patients battling solid tumors.

MonarchBio - Similar Companies

Encellin logo

Encellin

encellin.com

Mongoose Bio logo

Mongoose Bio

mongoosebio.com

NantBio logo

NantBio

Cell BioEngines logo

Cell BioEngines

cellbioengines.com

Appia Bio logo

Appia Bio

appiabio.com

Outpace Bio logo

Outpace Bio

outpacebio.com

A2 Biotherapeutics logo

A2 Biotherapeutics

a2bio.com

Inceptor Bio logo

Inceptor Bio

inceptor.bio

Manhattan BioSolutions logo

Manhattan BioSolutions

Xcell Biosciences logo

Xcell Biosciences

xcellbio.com

SymbioCellTech logo

SymbioCellTech

symbiocelltech.com

Nantkwest logo

Nantkwest

Geneius logo

Geneius

geneius.com

Mission Bio logo

Mission Bio

Shennon Biotechnologies logo

Shennon Biotechnologies

shennonbio.com

MonarchBio - Quick Facts

Who are MonarchBio's competitors?

Companies similar to MonarchBio include Encellin, Mongoose Bio, NantBio and Cell BioEngines.

When was MonarchBio founded?

MonarchBio was founded in 2011.

Where is MonarchBio's headquarters located?

MonarchBio's headquarters is located in Los Angeles, CA, US.

When was MonarchBio's last funding round?

MonarchBio's most recent funding round was for $1M (USD) in April 2020.

How much has MonarchBio raised to-date?

As of Apr 8, 2020, MonarchBio has raised a total of $1M (USD).

How many employees does MonarchBio have?

MonarchBio has 30 employees as of Feb 4, 2024.

MonarchBio - Classification

Industry
  • Hardware
Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cell Therapies
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software